# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> metformin, a safe Food and Drug Administration-approved antidiabetic drug, decreased leaky gut and inflammation in high-fat diet-fed older obese mice, by beneficially modulating the gut microbiota.

## Panel reviews

### `evidence_auditor` — `reject` (score 1)

The citation traces for C035 are completely nonsensical and indicate a total failure of the alias matching process. The trace claims that 'Food' resolved to 'YELLOW FEVER VACCINE' and 'Administration' resolved to 'BENZYDAMINE'. These are unrelated entities that bear no connection to the claim regarding metformin, FDA approval, or high-fat diet-fed mice. This represents a critical failure in the evidence trace, rendering the support for the claim invalid.

**Flagged claims:** C035

### `domain_skeptic` — `reject` (score 2)

The submission suffers from extreme mechanism inflation and a complete lack of human translation caveats. The claims are based entirely on a single study involving 'high-fat diet-fed older obese mice.' While the results may be valid for that specific rodent model, the thesis frames metformin as a 'safe FDA-approved antidiabetic drug' in a way that implies these gut-health benefits are generalizable or clinically relevant to humans, without explicitly limiting the scope of the conclusion to the murine model in the primary thesis statement.

**Flagged claims:** C035

### `final_judge` — `reject` (score 1)

I align with both the Evidence Auditor and the Domain Skeptic. The Evidence Auditor's finding is catastrophic: the citation trace for C035 shows a complete breakdown of the entity resolution process, where 'Food' and 'Administration' (parts of the phrase 'Food and Drug Administration') were erroneously mapped to 'YELLOW FEVER VACCINE' and 'BENZYDAMINE'. This indicates that the underlying evidence mapping is hallucinated or fundamentally broken, meaning there is no verified link between the cited literature and the claims made.

Furthermore, I agree with the Domain Skeptic regarding the lack of translational boundaries. The thesis presents a specific murine result as a general property of an FDA-approved drug without sufficient qualification. Given the combination of technical failure in the evidence trace and the overgeneralization of animal data, the submission is entirely unsupported.

**Flagged claims:** C035
